–
/ By Clive Minchom /
![kamada](https://jewishbusinessnews.com/wp-content/uploads/2013/04/kamada.png)
Earlier this month, Kamada guided for $74 million revenue in 2013, up from $73 million in 2012.
Kamada, which produces plasma-derived protein therapeutics, filed on Thursday with the SEC to raise up to $69 million in an initial public offering. The company’s shares are already listed on the Tel Aviv Stock Exchange under the symbol KMDA.
![](https://s3.amazonaws.com/media.jewishbusinessnews.com/2021/06/08195152/logo-full.png)